Saving Hearts, Kidneys and Lives in Type 2 Diabetes - Results from the FLOW Trial

In this episode of Diabetes Insights, we dive into the latest findings from the FLOW Trial - a groundbreaking trial evaluating the impact of GLP-1 receptor agonists on chronic kidney disease (CKD). This discussion features expert insights from Dr. Peter Rossing, Dr. Richard Pratley and Dr. Katherine Tuttle. The results reveal a 24% reduction in kidney disease progression, an 18% decrease in major cardiovascular events, and a 20% drop in total mortality - findings that could reshape clinical practice. Tune in to explore how this research is transforming diabetes and kidney disease management.